Amedisys Inc (AMED) Upgraded to Buy at Benchmark Co.
Benchmark Co. upgraded shares of Amedisys Inc (NASDAQ:AMED) from a hold rating to a buy rating in a research note released on Thursday morning. The brokerage currently has $56.00 price objective on the health services provider’s stock.
AMED has been the topic of several other reports. BidaskClub raised Amedisys from a sell rating to a hold rating in a research report on Friday, August 11th. Jefferies Group LLC reissued a buy rating and set a $60.00 price target on shares of Amedisys in a research report on Thursday, October 12th. SunTrust Banks, Inc. restated a buy rating and set a $60.00 price objective on shares of Amedisys in a research note on Monday, October 9th. Robert W. Baird restated a hold rating and set a $50.00 price objective on shares of Amedisys in a research note on Wednesday, October 4th. Finally, Royal Bank Of Canada restated a hold rating on shares of Amedisys in a research note on Monday, October 23rd. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Amedisys currently has a consensus rating of Buy and an average price target of $56.10.
Amedisys (AMED) traded up $8.35 during mid-day trading on Thursday, hitting $54.80. The company had a trading volume of 514,340 shares, compared to its average volume of 467,569. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.21 and a current ratio of 1.21. The firm has a market cap of $1,855.64, a price-to-earnings ratio of 28.99, a P/E/G ratio of 1.34 and a beta of 0.68. Amedisys has a twelve month low of $34.58 and a twelve month high of $65.91.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.watchlistnews.com/amedisys-inc-amed-upgraded-to-buy-at-benchmark-co/1679295.html.
In other news, insider David B. Pearce sold 1,000 shares of the stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total value of $50,000.00. Following the completion of the transaction, the insider now owns 10,488 shares of the company’s stock, valued at $524,400. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.00% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the company. Federated Investors Inc. PA grew its stake in shares of Amedisys by 2.3% in the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after purchasing an additional 44 shares in the last quarter. State Board of Administration of Florida Retirement System grew its stake in shares of Amedisys by 0.5% in the second quarter. State Board of Administration of Florida Retirement System now owns 19,658 shares of the health services provider’s stock worth $1,235,000 after purchasing an additional 93 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its stake in shares of Amedisys by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 6,590 shares of the health services provider’s stock worth $414,000 after purchasing an additional 220 shares in the last quarter. Suntrust Banks Inc. grew its stake in shares of Amedisys by 4.3% in the second quarter. Suntrust Banks Inc. now owns 5,702 shares of the health services provider’s stock worth $358,000 after purchasing an additional 237 shares in the last quarter. Finally, Texas Permanent School Fund grew its stake in shares of Amedisys by 1.2% in the second quarter. Texas Permanent School Fund now owns 20,439 shares of the health services provider’s stock worth $1,284,000 after purchasing an additional 243 shares in the last quarter. 96.86% of the stock is owned by institutional investors.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.